Please use this identifier to cite or link to this item:
|Title:||Neuroendocrine tumor liver metastases : use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response||Authors:||Miyazaki, K.
Orton, M. R.
Davidson, R. L.
d'Arcy, J. A.
Koh, T. S.
Thng, C. H.
Leach, M. O.
Collins, D. J.
|Keywords:||DRNTU::Engineering::Electrical and electronic engineering||Issue Date:||2012||Source:||Miyazaki, K., Orton, M. R., Davidson, R. L., d'Arcy, J. A., Lewington, V., Koh, T. S., et al. (2012). Neuroendocrine Tumor Liver Metastases: Use of Dynamic Contrast-enhanced MR Imaging to Monitor and Predict Radiolabeled Octreotide Therapy Response. Radiology, 263(1), 139-148.||Series/Report no.:||Radiology||Abstract:||Purpose: To evaluate dynamic contrast-enhanced (DCE) magnetic resonance (MR) imaging for monitoring and assessing treatment response in patients with neuroendocrine liver metastases treated using yttrium 90 (90Y)-labeled octreotide (90Y-DOTATOC). Materials and Methods: The study was approved by the local research and ethics committee and patient informed consent was obtained. Twenty patients with liver metastases from neuroendocrine tumors underwent T1-weighted DCE MR imaging of the liver before and at 2 months after intravenous 90Y-DOTATOC treatment. Regions of interest were drawn around target lesions, as well as along liver outlines for each patient. A dual-input single-compartment model was used to compute parameters including fractional distribution volume and the arterial flow fraction. Pre- and posttreatment values were compared using Wilcoxon signed rank test. Treatment response was defined as showing a greater than 50% reduction in the nadir chromogranin A level within the 1st year after treatment. Pretreatment values of responders and nonresponders were compared using the Mann-Whitney test. A two-tailed P value of .008 or less, which accounts for multiple testing, was considered to indicate a significant difference. Results: In responders, tumor and whole liver distribution volume significantly increased after treatment (median tumor distribution volume, 0.182 vs 0.244; median whole liver distribution volume, 0.175 vs 0.207; P = .008). The pretreatment whole liver distribution volume was significantly lower in responders (median, 0.175 vs 0.248; P = .003), while pretreatment tumor arterial flow fraction was significantly higher in responders (median, 1.000 vs 0.761, P = .006). Conclusion: DCE MR imaging may be used to monitor the effects of peptide receptor radiolabeled targeted therapy in patients with neuroendocrine tumors liver metastases; a lower pretreatment distribution volume and high arterial flow fraction was associated with a better response to treatment.||URI:||https://hdl.handle.net/10356/84807
|DOI:||10.1148/radiol.12110770||Rights:||© 2012 RSNA.||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||EEE Journal Articles|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.